key: cord-0898677-wmagnbgo
authors: Khorchani, Takoua; Gadiya, Yojana; Witt, Gesa; Lanzillotta, Delia; Claussen, Carsten; Zaliani, Andrea
title: SASC: A Simple Approach to Synthetic Cohorts for generating longitudinal observational patient cohorts from COVID-19 clinical data
date: 2022-02-09
journal: Patterns (N Y)
DOI: 10.1016/j.patter.2022.100453
sha: 2a6f601942376d5007f7f680daf899466c62e5d3
doc_id: 898677
cord_uid: wmagnbgo

One of the impacts of the COVID-19 pandemic has been a push for researchers to better exploit synthetic data and accelerate the design, analysis, and modelling of clinical trials. The unprecedented clinical efforts caused by COVID-19 will certainly boost future robust and innovative approaches of statistical sciences applied to clinical fields. Here, we report the development of SASC, a simple but efficient approach to generate COVID-19 related synthetic clinical data through a web application. SASC takes basic summary statistics for each group of patients and attempts to generate single variables according to internal correlations. To assess the “reliability” of the results, statistical comparisons with Synthea, a known synthetic patient generator tool and, more importantly, with clinical data of real COVID-19 patients are provided. The source code and web application are available on GitHub at https://zenodo.org/record/5896935#.Ye6cpnrMJgC.

In recent years, there has been growing interest in the re-use of clinic data for analysing patients' disease phenotype and their relative treatment. The COVID-19 pandemic has fuelled this interest due to the need for accelerated design and analysis of clinical trials. Developments that can rapidly analyse clinical data in a reproducible manner and in a secure and privacy-preserving environment have become increasingly necessary. A virtual patient (VP) could be an answer to these needs. First described in 1971 VPs were able to mimic real clinical scenarios with the help of a computer program 1 . Because of this, it then became possible to analyse physical exams, design diagnoses, and provide therapies based on a patient's clinical history 2 .

A collection of virtual patients forms a virtual cohort (VC). In this regard, VCs can support several professionals: a novice can aid in simulating different clinical scenarios (Association of American Medical Colleges 2007); a medical doctor could find suggestions for therapies for special patients, and in general, clinical statisticians can use VPs and VCs as the stimuli for problem-based learning approaches 3 . Indeed, the primary use of VCs began mainly for educational purposes 4 .

For creating synthetic data, there are at least two broad methodological categories to choose from, each with its own benefits and drawbacks. The first includes drawing numbers from distribution based on certain statistical methods, while the other uses agent-based or AI-based modelling methods. The latter of these approaches aims to explain an observed behaviour using a mathematical model for driving the data creation step 5 .

Belonging to the latest approach, the AI-driven methodologies are based on deep learning models, like Variational AutoEncoder (VAE) and Generative Adversarial Network (GAN). Another interesting approach based on Agent based 6 simulation has been published recently. All of these generation techniques are mainly devoted to capturing and preserving internal variable correlations. Even though these methods represent an improvement of the overall capability of synthetic data to mirror every aspect of the reality, their complexity sometimes makes them obscure and non-transparent 7 .

When talking about the mathematical models, they become more accurate when they get closer to observations seen in real populations. For this to happen, the variability of real patients must be taken into account thereby simulating diversity in virtual patients. In principle, a trivial method to generate VP is adding, for instance, random noise to existing real data 8 . However, this approach does not exert much success. The reason for this is the preservation of inter-and intra-patients' correlations which are of vital importance for a reliable VC generation 9 .

In addition to this, legal and ethical constraints are to be evaluated, which complicate the sharing and re-use of real patient-level data beyond summary statistics, even when anonymization is accomplished in Europe according to the General Data Protection Regulation (GDPR) (https://gdpr-info.eu/). This is true not only at the inter-organization level, but also at the intra-organization level 10 . Therefore, clinical data "silos" exist. This is increasingly becoming an issue as medicine as a whole is driven by the availability of Electronic Health Reports (EHR) where opportunities for digitalized storage, access, retrieval, and analysis, including the emerging use of Artificial Intelligence (AI), exist 11 . A practical way to overcome these objectives and legal hindrances could be the generative approach to very "realistic" patient-level data (i.e., a VC) possessing the same statistical features and properties of the source clinical data. The real advantage of this approach is manifold: first, clinical data often have missing data, which have to be imputed by the analyst wherever possible, while VCs contain no missing data if not inserted intentionally. Secondly, patient recruitment difficulties are obvious to overcome: practical recruitment restrictions or preferences, for example, gender, habit selection (e.g., only smokers), and geo-localization can be easily implemented, provided suitable reference "real" demographic data are available. Finally, "clinical-like" data can be inexpensive, while maintaining a high-quality level and thus, their modelling could improve clinical trial planning or analysis.

J o u r n a l P r e -p r o o f

In the present work, we describe SASC, a straightforward approach to generate VCs starting either from real patient-level data or from a summary table of a clinical trial. The VC generating script is the result of a multilateral effort including the collection of literature data as well as finding real anonymized clinical patientlevel data that is publicly available. The acquisition of anonymized clinical data, to which we compare the synthetic data, has been quite challenging work. Even though the quest for repurposed and effective therapies against the COVID-19 pandemic has generated numerous clinical trials, very few of them are easily accessible to researchers. Following the approach of Tucker et. al 12 and using the data contained in their supplementary materials, we designed the present study as a comparison between a real clinical dataset, results from Synthea and the synthetic datasets coming from SASC.

Fundamentally, numerical random generation under constraints is the core of SASC. This is true for both observational and interventional VCs, thereby assuring maintenance of intra-patient and cross-patient correlations that are important to achieving naturally "reliable" VC data, especially when there is only a qualitative assessment available for comparison. For a more quantitative assessment, several approaches have been offered 13, 14 . For simplicity, we did not generate metrics to compare cohorts similar to Tucker et. al. 12 given the scope of this work, but rather, focused on the similarity of single parameter distributions and their relative correlations. Both VCs generated by SASC and Synthea share a common principle: the longitudinal component in terms of medical visits (called 'encounters' in Synthea output) is generated patient-by-patient like a storybook in development 15 . The major difference between the two is that Synthea generates a mixed population of sick vs healthy VPs, while SASC generates only VPs with a predefined ratio of outcomes ( Figure 1 ).

Due to potential ethical issues relating to the use of the algorithm, we focus on possible methodological concerns following the classification of Mittelstadt et. al. 16 . For example, concerns implying causality can be directly excluded for SASC, as it does not generate therapeutic suggestions or causal dependencies between conditions and clinical parameters. Moreover, epistemic concerns (e.g. inconclusive or inscrutable evidence) should not affect SASC, as its code is transparent and public, and the risk of inconclusive or opaque decisions made on downstream machine learning tasks (using the SASC results) is not within SASC responsibility, in our view. Biases in the generation of variable values are likewise rare, as they are strictly dependent on the reference clinical data summary values (Table 1 and 2) . SASC, therefore, has the ability to recreate the same features of the reference cohorts (Table 3) and we tried to demonstrate this using a reference COVID-19 dataset.

Our study started from a public longitudinal observational COVID-19 cohort of 375 participants with limited demographic parameters and pharmacological variables. The participants' outcome was either deceased or survived and, thus, the first analysis was concerned with the identification and characterization of these pharmacological variables that showed the highest positive and negative correlation with the outcome ( Figure  2 ).

To demonstrate the validity of the process beyond the distribution shown above, we generated a correlation plot ( Figure 3 ) between the correlations of variables from real COVID-19 cohort and the SASC generated synthetic cohort to gender and hospitalization time. This was an exemplary choice as it was not practical to generate extended heatmaps or correlation plots for all the variables measured. Even though the distribution limits are maintained during the SASC variable generation process, it is not certain that the correlation is strictly maintained as the correlation depends also by the number of visits per patient and can differ after multiple SASC runs due to random generator. To simplify the complexity of quantitative comparison needed, we decide to track comparisons between real and generated synthetic variables by sampling their correlations to a common reference.

We also performed survival analysis both on gender and on age groups of participants. We noted well-known trends (Figure 4 ), including women showing higher hospitalization days with median survival probability and older patients showing less than half the hospitalization days at median survival probability than the other age groups. Kaplan-Meier analysis 20 and single parameter distribution comparison constitutes the minimal number of comparisons which our VC generation approach should satisfy in order to be assessed as a "realistic" VC and, thus, acceptable as an output ( Figure 5 ).

Resource availability

Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Andrea Zaliani (Andrea.Zaliani@itmp.fraunhofer.de).

The reference COVID-19 dataset was obtained from the Clinical Practice Research Datalink (CPRD) 17 . This synthetic dataset was based on real anonymized primary care patient data extracted from the CPRD Aurum database (https://www.cprd.com/primary-care) 18 . Patients were typically in primary care with symptoms of COVID-19 (confirmed/suspected) and control participants with a negative COVID-19 test result. For the purpose of this paper, we made use of the CRPD COVID-19 symptoms and risk factors synthetic dataset (Version 2021.04.001). The dataset contains information on sociodemographic and clinical risk factors from 03/12/2019 to 13/04/2021. The dataset has been made public also here: https://data.mendeley.com/datasets/ptz6zhknyp/1

For generating VC from Synthea, we have used the newly added COVID-19 module ( Figure 1A ) 19 . We have generated a 375-population cohort, whose data are available in Supplementary Materials. demographics (e.g., age and gender) from real data and used these probabilities to drive the generation of independent, normally distributed random values. Using this strategy, we generated participant outcomes (i.e., death and survival) too. Taking advantage of a table of grouped probabilities (Table 1) , we generated random variables normally distributed for each group of virtual patients for what concerns their outcome, age, gender, and visit numbers (see outcome, gender, and age in Table 2 ). All the other numerical variables have been generated on the basis of their grouped averages and standard deviations (as depicted in Table 1 ) under the given constraint of their correlations with outcome and/or gender, following a general principle described in the following link (https://stats.stackexchange.com/questions/15011/generate-a-random-variable-with-a-defined-correlation-toan-existing-variables/15035#15035). However, this generative step is only meaningful applied for existing correlations with Pearson's index higher than 0.6 in absolute value, and is not warranted for all. This is an aspect clearly visible in Figure 4 .

As the "hospitalization day" variable was used to analyse the events (death or survival) in the real clinical cohort, the optimal manner to mimic this variable was the number of visits performed within the same overall time span as that of the reference cohort. As this time range variable seemed to be important in the real cohort analysis, we decided to implement its variation within the SASC Shiny App, where two control sliders have been provided to users.

The overall workflow is depicted in Figure 1B . Table 1 For what concerns the generation of visiting time for all patients, we used the reference "hospitalization days" as a driving variable. From the hospitalization days distribution plot (Figure 7 and Table 1 ), it is clear that patients who did not survive had shorter hospitalization time, so we used maximal number of visits capped at seven and a time span of ten days, and we defined the longitudinal variable "hospitalization days" as the difference in time between the start of the study (fixed for all) and the last medical doctor's visit performed. This analysis generated the Kaplan-Meier plots reported in Figure 4 where it is evident that the age class and the gender survival patterns are retained qualitatively and quantitatively, both in terms of ranking and significance compared to the real cohort. As illustrated in Table 3 , the variable summary of the VC is close to that of the reference cohort shown in Table  1 . The main difference between the SASC-generated and reference grouped summary tables is the reduction in difference between genders based on mortality. The lowest difference is evident between the older and middleaged individuals. To display these results, we programmed a so-called Shiny app where we generated different VCs dynamically by modifying the two main parameters used (i.e., number of visits and time span of visits). Thus, this Shiny app supports users by generating diverse VCs according to the parameter chosen and provides an impression of the relative "reliability" of the VC synthetized. Table 3 Comparison of SASC cohort to real data

In order to further assess the reliability of the VC data generated, we conducted a comparison of the most relevant parameter distributions (absolute correlation with outcome >0.6) using the variables selected in figure 2 ( Figure  6 ).

SASC Shiny app (Figure 7) with its built-in survival analysis can provide similar display. When using specific parameters, users have a dynamical visual evidence on how far the generated VC lays from the survival analysis of the real clinical data. Upon identification of discrepancies, users can improve the method to generate a novel VC.

We have demonstrated that VCs generated using classical statistical parameters like mean and standard deviation can satisfy conditions for "reliability". In Figure 6 , the three sources of data (i.e., real, SASC, and Synthea cohorts) are compared in a boxplot for a selection of variables. Due to initial limitations of its novel COVID-19 module, Synthea did not generate two of the parameters: "Prothrombin activity" and "Fibrin degradation products" and hence their corresponding blue boxes are not present in the boxplot analysis. Moreover, some clinical measurements plays different roles whether they are generated in Europe or in US.

The Synthea module for COVID-19 is still in a beta version according to the authors, therefore, it is possible that it has not yet been optimized. Despite this, Synthea has been widely used in several other experiments allowing users to design modules, to add or modify parameters in case the cohort requires specific clinical design 19 . Moreover, it also provides FHIR formatted multi-output, which we did not use in this case 21 .

In our comparison reported herein, we have focused on clinically relevant parameters that provided a clear correlation with a real COVID-19 cohort outcome. All nine relevant parameters showed a positive or negative Pearson correlation > 0.6. Besides this, comparison between the limited demographic variables was performed as shown in Table 1 and 3. Synthea is US-centric and therefore uses US resident population data including demographic annotations, ethnicity, race, geo-localization in the US, marital status, smoking habits, etc. These parameters were absent in the real reference dataset and were thus excluded from the comparison. All numerical and ordinal data summarized in tabular format are derived from Figure 1A .

SASC, differently from Synthea, does not need any local installation and runs on the Web allowing users to download the results directly from it. Although the SASC shiny app has been dockerized and can run on cloud environments (such as Binderhub), in principle, any non-public cloud environment could be able to host this application. Synthetic data generated by SASC require pre-existing, ethically compliant clinical datasets. In this sense, SASC synthetized data are aimed towards education purposes or for validation of imputation techniques. Moreover, the COVID-19 observational reference studies for this analysis are typically of a few months' duration and correlations of parameters with gender or age can differ on longer timescales. SASC also implies normal distributions for the variables it generates which may not always be the case and this is a limitation of the method. An initial survey, however, elucidated that the variables were predominant in either normal or lognormal distributions. In this first version of SASC, we focused into the basic structure of the data generative model. Comparisons provided here are limited and we are actively working in defining novel but simple ways to compare real and virtual cohorts along the line of the work of Tucker et al. 12 . The different longitudinal dimension of the cohorts implies, in our eyes, the need to use robust and convenient summary of clinical variables per patient as comparative parameters. Comparisons among internal correlations, though, is a tough task and needs a study of its own.

When legal and ethical constraints influence sharing and re-use of health data, the generation of synthetic "reliable" participant data can be a viable solution if ethically compliant algorithms have generated them. As SASC only uses classical statistical distribution, the use of synthetic data is not only "safer" for participant data privacy but also represents a valuable source for exploratory data analysis (EDA), clustering approaches, testing of novel modelling imputation technologies, and development of analytical workflows. We report herein a simple and efficient R script tool aimed to generate VCs starting from a reference clinical dataset. The comparison to a real COVID-19 clinical cohort resulted in similar conclusions from Kaplan-Meier plots, which validates our approach. Schema followed for the generation of data for (A) Synthea (from https://synthetichealth.github.io/module-builder/#covid19/symptoms) and (B) SASC. Contrary to Synthea, SASC takes real clinical data at patient level as starting point, generates summary tables and relative grouped statistics according to demographics and outcomes, and for each desired n virtual patients, recreates relative demographics along with the number of visits. In the end, it provides a survival analysis on the synthetically generated clinical parameters. . The selection of the above variable intends to highlight the most outcome-correlated variables and, as such, the most relevant for downstream modelling attempts using the synthetic data generated by SASC. All variables, however, have been generated using the same methodology. The age group has been defined as "Young" with age <35, "Old" with age >60 and "Middle aged", all the remaining ages. Table 1 . Real cohort statistics -1. Summary table of relevant statistical parameters from the real COVID-19 cohort used in the SASC VC generating script. J o u r n a l P r e -p r o o f J o u r n a l P r e -p r o o f 

Virtual cohorts built on synthetic data have acquired attention lately as they can change the way we work with clinical data. Generating synthetic data very close to "real-world" data without having ethical restrictions can considerably help data analysts in several aspects such as didactic efforts, statistical modelling, and assessments of interventions. We developed SASC, a tool that uses summary statistics of real clinical data to produce synthetic data having the same or a very close summary to the reference variables. SASC displayed performance comparable with, or superior to, that of other virtual cohort tools like Synthea, and allows users to optimize the synthetic dataset produced through a Shiny visualizer application interactively.

From summaries of grouped variables is possible to generate synthetic data Similarity between real and virtual cohorts visualized with Kaplan-Meyer plots Shiny app for tuning and downloading the synthetic cohort provided to users SASC performances and results accuracies are similar or better to Synthea results

eTOC SASC shows that to generate virtual cohorts of patient-level data, no black-box tools are needed. More than acceptable dataset can be achieved without Neural network-based virtual cohort generators (e.g. GAN) where generation processes are difficult to be followed and understood. Starting from patient-level cohort data summaries of grouped variables, and using modified random number generation routine in R, synthetic dataset can be generated possessing quantitative characteristics similar to the real cohort, allowing in further analysis in an easy flow scheme.

CASE: a computeraided simulation of the clinical encounter

Virtual patients: a critical literature review and proposed next steps

Interactive simulated patient-an advanced tool for studentactivated learning in medicine and healthcare

AMEE Guide 32: e-Learning in medical education Part 1: Learning, teaching and assessment

Tutorial on agent-based modeling and simulation

Synthetic Reproduction and Augmentation of COVID-19 Case Reporting Data by Agent-Based Simulation

Dcnn augmentation via synthetic data from variational autoencoders and generative adversarial networks

Mathematical model of T-cell lymphoblastic lymphoma: disease, treatment, cure or relapse of a virtual cohort of patients

Next-generation, personalised, model-based critical care medicine: a state-of-the art review of in silico virtual patient models, methods, and cohorts, and how to validation them

Variational Autoencoder Modular Bayesian Networks for Simulation of Heterogeneous Clinical Study Data

From hype to reality: data science enabling personalized medicine

Generating high-fidelity synthetic patient data for assessing machine learning healthcare software

Development and verification of a" virtual" cohort using the National VA Health Information System

General principles for the validation of proarrhythmia risk prediction models: an extension of the CiPA in silico strategy

Synthea: An approach, method, and software mechanism for generating synthetic patients and the synthetic electronic health care record

The ethics of algorithms: mapping the debate

A machine learningbased model for survival prediction in patients with severe COVID-19 infection medRxiv 2020.02

Data resource profile: clinical practice research datalink (CPRD)

Synthea™ Novel coronavirus (COVID-19) model and synthetic data set. Intelligence-based medicine, 1, 100007

Nonparametric estimation from incomplete observations

We would like to thank Sarah Mubeen and Dr. Sheraz Gul for reviewing the manuscript and providing us with valuable suggestions. We are in debt with Dr. Jean-Marie Burel at University of Dundee for the support in the dockerization of the app.This research was done in the 'COPERIMOplus' initiative and supported by the Fraunhofer 'Internal Programs' under Grant No. Anti-Corona 840266.

The authors declare no competing interests.Further information and requests for resources should be directed to and will be fulfilled by the lead contact, Andrea Zaliani (andrea.zaliani@itmp.fraunhofer.de).